VBLT - Vascular Biogenics Trial Nears Full Enrollment Price Could Jump
- Vascular Biogenics recently resumed dosing American patients in its OVAL Phase 3 trial.
- Trial enrollment should complete in 1H 2022.
- If the data is positive, the stock price should jump considerably.
For further details see:
Vascular Biogenics Trial Nears Full Enrollment, Price Could Jump